Praluent 150 mg/mL

Alirocumab, the active ingredient in Praluent 150 mg/mL, is a PCSK9 inhibitor presented as a 150 mg/mL injection, solution for subcutaneous use. It is used as an adjunct to manage heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in patients who require additional lowering of LDL-cholesterol.

GNH USA supplies Praluent 150 mg/mL as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Praluent 150 mg/mL is a lipid-lowering agent used to manage cholesterol levels in specific conditions. It is indicated for patients who require additional lowering of LDL-cholesterol.

- Heterozygous familial hypercholesterolemia: Reduces LDL-cholesterol levels in patients with this genetic condition. - Homozygous familial hypercholesterolemia: Helps manage cholesterol levels in patients with this more severe inherited condition. - Primary hyperlipidemia: Lowers LDL-cholesterol in patients with primary hyperlipidemia. - Mixed dyslipidemia: Manages cholesterol levels in patients with mixed dyslipidemia.

Praluent 150 mg/mL may cause side effects, although not everyone experiences them. Common Side Effects: - Injection site reactions: Redness, swelling, or itching at the injection site. - Nasopharyngitis: Common cold symptoms. - Upper respiratory tract infection: Symptoms such as a runny or stuffy nose, sneezing, and sore throat. - Flu-like symptoms: General discomfort, fever, and fatigue. - Back pain: Discomfort or pain in the back. - Serious or Rare Side Effects: - Hypersensitivity reactions: Severe allergic reactions, including anaphylaxis. - Immune-mediated conditions: Development of autoimmune conditions. - Liver problems: Elevated liver enzymes or liver dysfunction. - Neurological symptoms: Memory problems or confusion.

Praluent 150 mg/mL should be used with caution in certain situations. Consult your healthcare provider for personalized advice. - Allergic reactions: Inform your doctor if you have a history of allergic reactions to alirocumab or any of its components. - Liver disease: Use with caution in patients with liver disease, as it may affect liver function. - Pregnancy: The safety of Praluent during pregnancy has not been established. Consult your doctor if you are pregnant or planning to become pregnant. - Breastfeeding: It is not known whether alirocumab passes into breast milk. Consult your doctor if you are breastfeeding. - Children: Safety and effectiveness in pediatric patients have not been established. - Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Praluent 150 mg/mL may interact with other medications, potentially affecting its efficacy or increasing the risk of side effects. Major Interactions (Avoid): - None identified. Moderate Interactions (Monitor Closely): - Other lipid-lowering drugs: Concurrent use with other lipid-lowering drugs may increase the risk of side effects. - Immunosuppressants: May increase the risk of infections. - Corticosteroids: May increase the risk of immune-mediated conditions. - Anticoagulants: May increase the risk of bleeding. - Antiplatelet drugs: May increase the risk of bleeding.